De Bono #AACR19 Lack of proof for clin utility. Onto circulating biomarkers: cfDNA conc. can be prognostic; cfDNA c… https://t.co/Kbb7Lh18BI
7:21am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Plenty of reasons of failure for validation and qualification; reproducibility crises of 11%. Insuf… https://t.co/Ql8iqwvTTm
De Bono #AACR19 Clinical qualification: for many biomarkers 'we have not done that' - like w/AR-V7 we have not done… https://t.co/EiD115MC8S
7:20am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Repro: intra-lab, inter-lab, biological variability across time. Diurnal rhythm, fasting/fed, exercise.
7:18am April 1st 2019 via Twitter Web Client
De Bono #AACR19 The devil in the details with analytical validation: LoD, FNs, continuous variables are preferred o… https://t.co/ZxdTeRE1Fn
De Bono #AACR19 If good prognosis: you have a problem; you'll need large randomized trials... The process of obtain… https://t.co/EzjgrXAvsN
7:16am April 1st 2019 via Twitter Web Client
De Bono #AACR19 PTEN loss: studying a PhIII Roche drug: AKT-blockade. Both prognostic and predictive: if prog of po… https://t.co/cy2BXO4lgV
7:14am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Pre-Rx: can be difficult to dissect the prognostic from the prognostic AND predictive. AR7 splice v… https://t.co/MMxBMJjjiZ
7:13am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Pre-cancer Dx: risk markers (BRCA); Dx (BCR-ABL); pre-Rx: prognostic (Ki67) or predict (guide Rx);… https://t.co/M0sTjeZa0d
7:11am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Ex of markers: blood press; HIV viral load; HER2 and ER in Br cancer. Shows slide #3 from this FDA… https://t.co/jXPuc6QobX
7:09am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Whole blood GEX (WBC), looking at myeloid cell's involvement with PrCa. Assuming: people knowing le… https://t.co/DjPhXf9SHh
7:07am April 1st 2019 via Twitter Web Client
De Bono #AACR19 PrCa: after Rx, 2-3 mo the drug doesn't work, you don't learn anything. Spent a lot of time w/CTC.… https://t.co/AM9qiz8cZD
7:06am April 1st 2019 via Twitter Web Client
De Bono #AACR19 Has been working on circulating biomarkers since '07; early trials 'were not really interpretable' - needed more info.
7:05am April 1st 2019 via Twitter Web Client
Johann De Bono (Royal Marsden UK) #AACR19 Impacting cancer research and patient care through circulating biomarkers
7:03am April 1st 2019 via Twitter Web Client
#AACR19 Q:Antigen retrieval? Akoya Kennedy-Darling: Analysis and retrieval on the coverslip isn't standard, current… https://t.co/Qm7d3d0Xqm
2:33pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Aqua analysis invented '99. Patented '07, owned by Novartis in '13 (Navigate biopharma, limited dist.)
2:31pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: QIF: how deep the stain goes? Est only 1-1.5um. Depth may not be important, rather diffusion.
#AACR19 Akoya Q: How thick can CODEX go? Rimm: Up to 10um. Higher - can the Ab get to the tissue. Need to also optimize fluidics protocol.
2:30pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Q: One objection is archiving Rimm: Pretty soon we won't have glass at all for archiving (only digital).
2:29pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Q: Calibration - do you normalize across specimens? Rimm: Can't normalize out pre-analytical var's.
2:28pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Hypothesis - talking on Monday, MOA is on macrophages binding PD-L1; when inhibited, macrophage… https://t.co/axCwVIXxMQ
2:26pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Points to this https://t.co/LQ1dUZE83d and https://t.co/6bg3cC9kRu showing high correlation bet… https://t.co/2ZCbaqLsen
2:23pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Concl "Counting and measuring are related but not equal'. Counting more accurate with rare events.
2:21pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: PFS and OS of RECIST categories - retrospective analysis looking at the charts, validating their criteria.
2:17pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: The problem w/% cells pos: you still need a threshold. Points to this recent CCR piece… https://t.co/qm88PQI5tD
2:16pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Measuring cells with chromagens: percent positive cells, and count via phenotypes. QIF: what's… https://t.co/2fcud6T1Jk
2:14pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: "15y ago when we started everyone thought we were nuts, now everyone is doing (QIF)"
2:13pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Inter-site PD-L1 R2 = 0.81. Taking human judgement out - MITRE w/ QIF represents the first pros… https://t.co/a4aEOZgQvu
#AACR19 Akoya Rimm: Tonsil CD20 slides: new LEDs reduces unmixing issues. Inter- and intra-site. MITRE initial resu… https://t.co/vewOqKOb1y
2:12pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Measuring stain intensity; started with lymph, and cell line TMA ('control pellets') with neg,… https://t.co/ZPZpqeuxo7
2:10pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Standards for quantitative fluorescence - a standardization TMA. Their mIF panel: PD-L1, Cd8, F… https://t.co/elJHCecAdo
#AACR19 Akoya Rimm: A 6-plex panel: PDL1, PD1, CD8, CD68, Foxp3, tumor (CK/lung, Sox10%S100/mel).
2:08pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Results under embargo and will be published 'soon'. MITRE: have a drug, "a validation of the QI… https://t.co/oo9Lkw22hC
2:07pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: Interesting - combinations of modes - get to 0.802 (multiplex IF + IHC). QIF of 0.8 has a low n… https://t.co/L0bjNlLGbK
2:06pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: AUC of metaanalysis for measurements for I/O https://t.co/sTB22EpnNj
2:05pm March 31st 2019 via Twitter for iPhone
#AACR19 Akoya Rimm: At SITC: Steve Lu (Hopkins) to compare biomarker assay modalities (PD-L1) and make AUC curves.… https://t.co/kLamwfJ1Wc
2:03pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Rimm: His disclosure slide is busy because biotech is moving this from the lab to the clinic. Will ta… https://t.co/xQl864FR6j
2:02pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya David Rimm (Yale) Dir of Yale Pathology Tissue Services title: Immunofluorescence - from the lab to the clinic?
2:01pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Working on signal amplification (lowering damage to lower exposure times). Typically… https://t.co/xqkljH1Xta
1:59pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Shows cell proximity by cell-type from the 2D analysis of breast cancer data.
1:57pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: FF lymph node from breast cancer pt: 29 marker staining; DAPI stain with .fcs file (… https://t.co/a10Bg2Nh4T
1:55pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Shows overlay data of FFPE human renal cell carcinoma with CODEX tissue analysis, al… https://t.co/o4qcJ95VVK
1:53pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Shows signal saturation / noise with titer data for spec Abs. Look at +/- countersta… https://t.co/MEDIJ8XdRH
1:50pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Also comparing tissues to databases with known targets. Threshold image of signal/no… https://t.co/wNWNyOYu9S
1:49pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Microscopes are controlled directly by their software. Image processing SW and image… https://t.co/7lVmhA4eJ3
1:48pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Tissue slices onto coverslips, inserted onto stage + gaskets; fluids controlled by Akoya instrument.
1:47pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Dist of Abs 'across 4 channels'. Four fluors, can use Alexa 750. CODEX integrates wi… https://t.co/KWkdzdYkvu
1:46pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Shows no signal dropoff from cycle 1 to cycle 11. Reagents: kits for staining, conju… https://t.co/KEiI5x87c3
1:45pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Shows CD38 staining of signal ROI (threshold) cp to noise ROI. Shows high signal/noise, with low carryover.
1:43pm March 31st 2019 via Twitter Web Client
#AACR19 Akoya Kennedy-Darling: Repeating process 16+ times. Shows movie - human tonsil, shows same tissue stained 1… https://t.co/0o4siUXSWd
1:41pm March 31st 2019 via Twitter Web Client
